News and events
Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care
Oncologists like Dr Doug Flora and Dr Debra Pratt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened. “The key is, MRD (minimal residual disease testing)
Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development
Haystack technology in action at ASCO 2024!
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus’ TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development
Recent events
Haystack MRD™ by Quest Diagnostics® at SSO 2025
We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack
Haystack MRD™ by Quest Diagnostics at ASCO GI 2025
We are excited to announce our participation in the 2025 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI) taking place January 23-25 in San Francisco, CA. Join us
Visit us at 2024 SABCS® – Shaping the Future of Breast Cancer Care
Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual
